Slide 1: GenScript Biotech Corporation 2022 Annual Results Presentation
GenScript Biotech Corporation Make People and Nature Healthier through Biotechnology 2022 Annual Results Presentation Stock Code: 1548.HK
Slide 2: Disclaimer
Disclaimer Forward-Looking Statement This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although
Slide 3: Contents
CONTENTS 01 Business Highlights 02 Financial Performance 03 Future Strategies
Slide 4: Business Highlights
Business 01 Highlights
Slide 5: Segment Highlights
Segment Highlights Life Science Services and Products Biologics CDMO • 21 years of consecutive growth • Revenue growth ~54% YoY, constant currency growth 59.3% • Revenue growth 14.2% YoY, organic revenue growth 22.6% YoY • 50/50 domestic and international sales • Customer number reached ~50,000, up
Slide 6: GenScript Life Science Group
GenScript Life Science Group Molecular Biology Life Science- • No.1 gene synthesis provider worldwide Innovation drives • GenTitan ™ Gene Fragment Service enabled by chip based synthesis • Application-driven service design (ADD, GCT, mRNA, and syn-bio related long-term applications) sustainable grow
Slide 7: Continued Recognition from Customers
Continued Recognition from Customers Customer Composition1 Customer Count1,2 25% 23% Pharma/Biotech 49k+ 50% Non Profit Organization 2021 Industrial/Applied 2022 54% 46k+ 25% 23% 2021 2022 Regional Sales Performance1,3 Scientific Journal Citations 2021 2022 10k+ 9k+ China Overseas 2021 2022 1. Manag
Slide 8: Global Capacity Expansion
Global Capacity Expansion -2022 China, Singapore, 2023，US 南京 66,090 ft² Nanjing Life Science Services and Instruments 11,625 ft² Singapore MB Lab 55,972 ft² Piscataway MB Lab1 271,680 ft² Zhenjiang Life Science Building -2023 Zhenjiang Piscataway MB Lab Singapore MB Lab 213,986 ft² Zhenjiang Molecul
Slide 9: GenScript ProBio — One-Stop Solution CDMO Biologics
GenScript ProBio — One-Stop Solution CDMO Biologics Discovery Protein & Antibody Drug Therapeutic TAT & success rate improvement New vector design to boost titer up to 15g/L Protein& Antibody • TAT of hybridoma approach is under Shorten cell line development 12 weeks Services timeline to 12 weeks, C
Slide 10: GenScript ProBio — One-Stop Solution CDMO Gene and Cell Therapy
GenScript ProBio — One-Stop Solution CDMO Gene and Cell Plasmid Viral vector Therapy CDMO Launched GMP plasmid platform, scale up to 300L Proprietary suspension cell line PowerSTM-293T • >70 batches 50L GMP LVV Established capabilities to production delivered with high final develop and manufacture
Slide 11: GenScript ProBio — Proven Track Record
GenScript ProBio — Proven Track Record Biologics New Projects GCT New Projects mRNA one-stop Platform 2021 mAb 2022 2021 Plasmid 2022 Novel Modality Viral Vector 24 CMC 36 CMC 61 CMC 55 CMC3 10 IND Approval 8 IND Approval 6 IND Approval 14 IND Approval Track Record in Biologics Track Record in GCT ⚫
Slide 12: Bestzyme Enhanced Core Competitiveness
Bestzyme Enhanced Core Competitiveness • Completed 6 products‘ strain development R&D • Launched new products for household care and Competitiveness animal feed • State of art automated manufacturing facility Manufacturing • Fermentation, extraction, compound process Efficiency optimization • Enhanc
Slide 13: Synthetic Biologic Pipelines
Synthetic Biologic Pipelines Scoping Discovery Development Launch Natural Protein sweeteners offer health benefit and 2024 Sweeteners better flavor profile Nutrition Food & Heme Flavoring and coloring for plant based 2024 Protein food BSJ23B01 A bioactive protein 2025 Chemical Specialty Enzymatic pr
Slide 14: CARVYKTI Commercial Approval and Global Manufacturing
CARVYKTI Commercial Approval and Global Manufacturing CARVYKTI (cilta-cel) US Facilities EU Facilities China Facilities Commercial Approvals Approved by the US FDA on February 28, 2022 Raritan, NJ Ghent, Belgium Nanjing Conditional Approval by the EC on May 26, 2022 BCMA US / EU / JP / ROW Future Co
Slide 15: Robust Pipeline
Robust Pipeline Pre-clinical Phase I Phase II Phase III NSCLC GASTRIC & NHL† /ALL† RRMM (BCMA) RRMM (BCMA)* RRMM (BCMA)* ESOPHAGEAL& (CD19 X CD20 X CD22)† LEGEND-2† CARTIFAN-1 (GPC3) 1-3 Prior Lines PANCREATIC ‡ Autologous Autologous Autologous Autologous CARTITUDE-4 (CLAUDIN 18.2) NCT05318963 NCT03
Slide 16: Financial Performance
Financial 02 Performance
Slide 17: Financial Highlights
Financial Highlights Group Level Non-cell Therapy Cell Therapy 625.7m +27.7% 509.0m +19.8% 117.0m +70.0% Revenue External Revenue Revenue 304.1m 268.1m 53.0m +7.6% +17.4% Versus 68.8m in 2021 Gross Profit Adj. Gross Profit1 Adj. Gross Profit1 -359.4m 62.4m -422.1m Versus -327.8m in 2021 +31.4% Versu
Slide 18: Investment to Fuel Future Growth
Investment to Fuel Future Growth 2-Year Adjusted R&D ($M)1 Majority of R&D on Cell Therapy 47.6 55.0 • Cilta-cel program global clinical trials • New cell therapy pipeline Non-Cell Therapy segments 10.6% of Revenue in R&D 300.5 316.6 • Novel life science tools and services • Improvement of AAV and m
Slide 19: Life Science Financial Performance
Life Science Financial Performance 360.5m 201.1m 66.1m Revenue Adj. Gross Profit2 Adj. Operating Profit2 14.2 % 22.6 % 8.0% 18.3%/Rev. Revenue growth Organic growth1 $m Revenue Breakdown Selling and 54.4 Distribution Expenses Molecular Bio. Protein & Ab Administrative 47.8 Expenses 2021 Peptide 2022
Slide 20: Biologics CDMO Financial Performance
Biologics CDMO Financial Performance 125.0m 42.8m 233.3m 15.2m Revenue Adj. Gross Profit2 Backlog Adj. EBITDA2 53.6 % 59.3 % 54.5% 18.2% 12.2%/Rev. Revenue growth Organic growth1 $m Revenue Breakdown Selling and 15.3 Distribution Expenses Administrative Biologic 24.9 Expenses 2021 2022 GCT Research
Slide 21: Industrial Synthetic Biology Financial Performance
Industrial Synthetic Biology Financial Performance 38.7m 16.6m 2.9m Revenue Adj. Gross Profit1 Adj. Operating Profit1 Versus 38.6m in 2021 46.9% 7.5%/Rev. $m Revenue Breakdown Selling and 3.6 Distribution Expenses Administrative Feed Enzyme 5.5 Expenses 2021 Syn-Bio 2022 Industrial Enzyme Research a
Slide 22: Cell Therapy Financial Performance
Cell Therapy Financial Performance 117.0m 70.0% -422.1m Revenue Versus -372.4m in 2021 Adj. Net Loss1 50.0m 66.7m $m Selling and 93.4 Milestone Share of CARVYKTI sales Distribution Expenses Administrative Cilta-cel Upfront Payment & Milestones2 80.6 Expenses Q1 $350M Jul $25M Jan $30M May $15M Feb $
Slide 23: Future Business Strategies
Future Business 03 Strategies
Slide 24: Future Business Strategies
Future Business Strategies • Increase R&D to enable • Expand our target • Enhance tech transfer • Improve cilta-cel GCT service & product: customer in from R&D to industrial- production capacity to NVP, Cell Isolation, etc international grade manufacturing support established biotech to commercializ
Slide 25: Thanks
Thanks For More Information：https://www.genscript.com/